Evidence map›Paper›PMID 40635081›Full record

ArticleEuropean journal of medical research2025

Identification of FANCG as a prognostic factor for prostate cancer.

Wenlong Gao, Peng Liu, Han Xinyue, Yuanjie Niu, Wu Yi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Double jeopardy: howFrontiers in cell and developmental biology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wenlong Gao *Department of Urology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Peng Liu *Nankai University, Tianjin, 300211, China.
Han XinyueDepartment of Urology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Yuanjie NiuNankai University, Tianjin, 300211, China. yuanjieniuo1@outlook.com.
Wu YiDepartment of Urology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China. wuy6250@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo ascertain role of the fanconi anemia complementation group G (FANCG) gene in prostate cancer (PCa) and the suitability of the FANCG gene as a prognostic biomarker for PCa.

methodsWe assessed the expression of FANCG using an analysis of publicly available data sets and cell lines. Physiological functioning of the cells was evaluated through MTT assays and migration assays. Co-expressed genes and enrichment analysis were conducted to probe the biological significance of FANCG in PCa. Quantitative real-time polymerase chain reaction (qPCR) was utilized to detect the expression levels of hub genes (MCM7, MCM5, POLD1, POLA2, LIG1) associated with FANCG.

resultsWe observed a significant upregulation of FANCG expression in PCa patients and cell lines. Furthermore, immunohistochemical analysis demonstrated markedly higher FANCG protein expression in PCa tissues compared to non-cancerous PCa tissues. Downregulation of FANCG significantly inhibited cell proliferation and migration potential. Evaluation of FANCG-related hub genes (MCM7, MCM5, POLD1, POLA2, and LIG1) revealed their close association with cell cycle-related signaling pathways. Upregulation of FANCG mRNA expression in PCa tissues significantly correlated with high serum PSA levels, advanced pathological stage, high Gleason score, shorter overall survival time, and shorter disease-free survival time.

conclusionsThis study suggests that FANCG likely plays a pivotal role in PCa progression. In addition, increased FANCG expression may serve as an indicator of poor disease-free survival and an adverse prognosis for PCa patients.

Indexed as

Biomarkers, TumorFanconi Anemia Complementation Group G ProteinProstatic NeoplasmsAgedCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisBiomarkers, TumorFANCG protein, humanFanconi Anemia Complementation Group G ProteinBioinformaticsFanconi anemia complementation group GPrognostic factorProstate cancer

Identifiers

PMID40635081
PMCPMC12239328

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.